Person: YILDIZELİ, BEDRETTİN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
YILDIZELİ
First Name
BEDRETTİN
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Perioperative management of massive pulmonary hemorrhage after pulmonary endarterectomy(BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK, 2018) YILDIZELİ, BEDRETTİN; Yildizeli, Sehnaz Olgun; Erkilinc, Atakan; Yanartas, Mehmed; Tas, Serpil; Sunar, Hasan; Gurcu, Emre; Yildizeli, BedrettinBackground: This study aims to evaluate our approaches and outcomes in patients who developed hemoptysis following pulmonary endarterectomy. Methods: Pulmonary endarterectomy was performed in 460 patients at Kartal Kosuyolu Training and Research Hospital between March 2011 and September 2017. Clinical characteristics, perioperative management and postoperative outcomes of 10 patients (2.1%) (4 males, 6 females; mean age 48.3 +/- 16.5 years; range 21 to 76 years) with massive pulmonary hemorrhage following pulmonary endarterectomy were evaluated. Results: Mean period of diagnosis for chronic thromboembolic pulmonary hypertension was 17 +/- 13.6 months. All patients were New York Heart Association functional class II (n=2), III (n=5) or IV (n=3). For the treatment of massive pulmonary hemorrhage, intraoperative extracorporeal membrane oxygenation was used in six patients (60%), while conservative treatments were used in four patients (40%). In-hospital mortality rate was 50% (n=5); the causes for mortality were septic shock in two patients, multiple organ failure in two patients and intracranial hemorrhage in one patient. Survival was achieved in two patients on extracorporeal membrane oxygenation and three patients receiving conservative treatment. Functional and hemodynamic improvement was observed in all surviving patients. Conclusion: Despite the relatively low incidence of massive pulmonary hemorrhage after pulmonary endarterectomy, it is a potentially fatal complication. Our approach focuses on early diagnosis with a multidisciplinary team and management with bronchoscopy, bronchial blockers and use of extracorporeal membrane oxygenation. The choice of treatment depends on the site and origin of the hemorrhage, the availability of equipment and expertise, and the potential short- and long-term advantages and disadvantages.Publication Metadata only Trombin jenerasyon zamanı ve endotel disfonsiyon belirteçlerinin pulmoner endarterektomi sonuçlarına etkisi(2023-10-19) ERMERAK, NEZİH ONUR; LAÇİN, TUNÇ; TOPTAŞ, TAYFUR; OLGUN YILDIZELİ, ŞEHNAZ; AK, KORAY; YILDIZELİ, BEDRETTİN; TİRYAKİ G. G., Ertan R., Pasayev J., ERMERAK N. O., LAÇİN T., TOPTAŞ T., OLGUN YILDIZELİ Ş., Taş H., AK K., YILDIZELİ B.Publication Metadata only Does tapse/spap ratio predict early outcome followingpulmonary endarterectomy(2023-06-04) OLGUN YILDIZELİ, ŞEHNAZ; ERMERAK, NEZİH ONUR; MUTLU, BÜLENT; KOCAKAYA, DERYA; AK, KORAY; BEKİROĞLU, GÜLNAZ NURAL; YILDIZELİ, BEDRETTİN; TİRYAKİ G. G., Ertan R., OLGUN YILDIZELİ Ş., ERMERAK N. O., MUTLU B., KOCAKAYA D., TAŞ S., AK K., BEKİROĞLU G. N., YILDIZELİ B.Publication Metadata only Covid sonrası gelişen diğer bir uzun dönem komplikasyon ve cerrahi tedavisi: Post-Covid KTEPH(2022-11-05) ERMERAK, NEZİH ONUR; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; MUTLU, BÜLENT; AK, KORAY; YILDIZELİ, BEDRETTİN; ERMERAK N. O., OLGUN YILDIZELİ Ş., KOCAKAYA D., TİRYAKİ G. G., Güçtekin Y., MUTLU B., AK K., TAŞ S., YILDIZELİ B.Publication Metadata only Outcomes of Patients with Behcet's Syndrome after Pulmonary Endarterectomy(GEORG THIEME VERLAG KG, 2018) YILDIZELİ, BEDRETTİN; Yildizeli, Sehnaz Olgun; Yanartas, Mehmed; Tas, Serpil; Direskeneli, Haner; Mutlu, Bulent; Ceyhan, Berrin; Yildizeli, BedrettinBackground Behcet's syndrome (BS) is a multisystem disorder and is not known as a risk factor for chronic thromboembolic pulmonary hypertension (CTEPH), for which the treatment of choice is pulmonary endarterectomy (PEA). The aim of this study was to review our experience in the surgical treatment of CTEPH in patients with BS. Methods Data were collected prospectively for consecutive patients with BS who underwent PEA over a 6-year period. Results We identified nine patients (seven males, two females, mean age: 34.79.9 years) with BS. The mean disease duration before PEA was 88.0 +/- 70.2 months. All patients but one received immunosuppressive therapy before the surgery. Exercise-induced dyspnea presented symptoms in six patients. One patient had associated intracardiac thrombosis. PEA was bilateral in five patients, unilateral in three, and lobar in one. No perioperative mortality was observed; however, one patient died four weeks after PEA due to massive hemoptysis. Morbidity was observed in two patients. The systolic pulmonary artery pressure fell significantly from 59.0 +/- 22.7mm Hg to 30.0 +/- 6.5mm Hg after surgery ( p =0.031). Pulmonary vascular resistance also improved significantly from 611.8 +/- 300.2 to 234.7 +/- 94.9 dyn/s / cm (5) ( p =0.031). After a median follow-up of 29.4 months, all patients improved to the New York Heart Association (NYHA) functional class I and II. Conclusion Patients with BS may suffer recurrent pulmonary embolism and develop CTEPH. In patients who do not respond to anticoagulation or immunosuppressive therapy, PEA may be a therapeutic option when thrombotic lesions are surgically accessible. Due to the high risk of perioperative mortality, the procedure should be undertaken in centers with experience.Publication Metadata only Pulmoner arter sarkomanın cerrahi sonuçları: Histoloji sağkalımı etkiler mi(2023-08-01) BOZKURTLAR, EMİNE; OLGUN YILDIZELİ, ŞEHNAZ; MUTLU, BÜLENT; KOCAKAYA, DERYA; BEKİROĞLU, GÜLNAZ NURAL; YILDIZELİ, BEDRETTİN; Başar V., Olgun Yıldızeli Ş., Bozkurtlar E., Ercelep ., Mutlu B., Kocakaya D., Bekiroğlu G. N., Taş S., Sunar H., Küçükoğlu M. S., et al.Publication Metadata only Extracellular matrix collagen biomarker levels in patients who underwent pulmonary endarterectomy(2023-04-01) OLGUN YILDIZELİ, ŞEHNAZ; MUTLU, BÜLENT; YILDIZELİ, BEDRETTİN; Zengin A., Kalkan R., Aydin K. Y., OLGUN YILDIZELİ Ş., MUTLU B., Karakoc A. Z., Tas S., Sunar H., Kilic U., Yanartas M., et al.OBJECTIVES: The role of extracellular matrix collagen biomarkers in chronic thromboembolic pulmonary hypertension (CTEPH) is not well known. Our goal was to investigate the matrix metalloproteinase (MMP)-2 and -9 protein levels in patients with CTETH.